Pfizer's quarterly profit rises 14 per cent
The largest US drugmaker said on Tuesday net profit rose to $3.56 billion or 59 cents per share in the first quarter of 2018, from $3.12 billion or 51 cents per share a year earlier.01-05-2018
01-05-2018
Board to consider FY18 results & Dividend on May 07, 2018
Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 07, 2018, inter alia, to consider and take on record the Audited Financial Results of the Company for the financial year ended March 31, 2018.At the said meeting, the Board of Directors will also consider recommendation of dividend, if any, for the financial year ended March 31, 2018....26-04-2018
Board Meeting For The Audited Financial Results For The Financial Year Ended March 31, 2018 And Intimation Of Closure Of Trading Window.
This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 7, 2018, inter alia, to consider and take on record the Audited Financial Results of the Company for the financial year ended March 31, 2018. At the said meeting, the Board of Directors will also consider recommendation of dividend,if any, for the financial year ended March 31, 2018....26-04-2018
Shareholding for the Period Ended March 31, 2018
Pfizer Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018. For more details, kindly Click here13-04-2018
Statement Of Investor Complaints For The Quarter Ended March 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 027252 Name of the Signatory :- PRAJEET NAIRDesignation :- Company Secretary and Compliance Officer11-04-2018
Compliance Certificate - Regulation 7(3) Of The SEBI (LODR) Regulations, 2015
In compliance with Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Certificate from the Company and the Registrar and Share Transfer Agent for the half year ended March 31, 2018.11-04-2018
Compliance Certificate - Regulation 40 (9) Of The SEBI (LODR) Regulations, 2015
In compliance with Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Certificate given by the Practicing Company Secretary, M/s. Manish Ghia & Associates, for the half year ended March 31, 2018.11-04-2018
GSK backs out of $20 bn bidding race for Pfizer's consumer health-care unit
Pfizer is the world's fifth-largest player in consumer health with 2.5 percent of a market bolstered by ageing populations and growing interest in health and wellness23-03-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, enclosed herewith are the details of the meeting scheduled with an Analyst/Institutional Investor. Please note that the enclosed schedule is subject to change on account of exigencies on the part of the Analyst/Institutional Investor or the Company. The enclosed schedule shall also be displayed on the website of the Company - www.pfizerindia.com in compliance with the Regulation 46 of the Listing Regulations.19-03-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Listing Regulations, enclosed herewith are the details of the meeting scheduled with an Analyst/Institutional Investor. Please note that the enclosed schedule is subject to change on account of exigencies on the part of the Analyst/Institutional Investor or the Company. The enclosed schedule shall also be displayed on the website of the Company - www.pfizerindia.com in compliance with the Regulation 46 of the Listing Regulations.19-03-2018